Title : Synthesis, biological evaluation, and docking studies of some 5-chloro-2(3H)-benzoxazolone Mannich bases derivatives as cholinesterase inhibitors - Uysal_2018_Arch.Pharm.(Weinheim)_351_e1700273 |
Author(s) : Uysal S , Parlar S , Tarikogullari AH , Aydin Kose F , Alptuzun V , Soyer Z |
Ref : Arch Pharm (Weinheim) , 351 :e1700273 , 2018 |
Abstract :
A series of N-substituted-5-chloro-2(3H)-benzoxazolone derivatives were synthesized and evaluated for their acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) inhibitory, and antioxidant activities. The structures of the title compounds were confirmed by spectral and elemental analyses. The cholinesterase (ChE) inhibitory activity studies were carried out using Ellman's colorimetric method. The free radical scavenging activity was also determined by in vitro ABTS (2,2-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)) assay. The biological activity results revealed that all of the title compounds displayed higher AChE inhibitory activity than the reference compound, rivastigmine, and were selective for AChE. Among the tested compounds, compound 7 exhibited the highest inhibition against AChE (IC50 = 7.53 +/- 0.17 muM), while compound 11 was found to be the most active compound against BuChE (IC50 = 17.50 +/- 0.29 muM). The molecular docking study of compound 7 showed that this compound can interact with the catalytic active site (CAS) of AChE and also has potential metal chelating ability and a proper log P value. On the other hand, compound 2 bearing a methyl substituent at the ortho position on the phenyl ring showed better radical scavenging activity (IC50 = 1.04 +/- 0.04 mM) than Trolox (IC50 = 1.50 +/- 0.05 mM). |
PubMedSearch : Uysal_2018_Arch.Pharm.(Weinheim)_351_e1700273 |
PubMedID: 29527733 |
Uysal S, Parlar S, Tarikogullari AH, Aydin Kose F, Alptuzun V, Soyer Z (2018)
Synthesis, biological evaluation, and docking studies of some 5-chloro-2(3H)-benzoxazolone Mannich bases derivatives as cholinesterase inhibitors
Arch Pharm (Weinheim)
351 :e1700273
Uysal S, Parlar S, Tarikogullari AH, Aydin Kose F, Alptuzun V, Soyer Z (2018)
Arch Pharm (Weinheim)
351 :e1700273